← Back to Search

Behavioral Intervention

Intervention: Motion Reset for Healthy Subjects

N/A
Waitlist Available
Led By Susan Persky, Ph.D.
Research Sponsored by National Human Genome Research Institute (NHGRI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during and after vr use
Awards & highlights

Summary

Background: People use virtual reality (VR) technology to play games, socialize, work, or receive medical care. Some people have "cybersickness" after using VR. Cybersickness is similar to motion sickness. Symptoms include eye strain, nausea, dizziness, or headache. The symptoms are usually mild and go away after the person stops using VR. New software called Motion Reset is being designed to reduce symptoms of cybersickness during VR use. Objective: To see if Motion Reset software can reduce cybersickness in people using VR. Eligibility: Healthy adults aged 18 to 60 years. Design: Participants will have 1 clinic visit that will last about 1 hour. They will answer questions about how they are feeling. They will learn how to use the VR headset and the handheld game controllers. The study will be broken into 2 parts. For the first part, participants will be assigned to 1 of 3 groups: Group 1 will participate in a VR experience designed to prevent cybersickness. They will view screens and move around while they press buttons on a controller. Group 2 will participate in a VR experience that is not designed to prevent cybersickness. They will view screens and move around while they press buttons on a controller. Group 3 will have no VR experience. Participants will complete 2 questionnaires about their experiences in the first part of the study. For the second part, all participants will spend up to 20 minutes playing a commercial VR game called Jurassic World Aftermath. Every few minutes, they will be asked if they are experiencing discomfort. After playing the game, participants will complete 12 questionnaires about their experience.

Who is the study for?
This trial is for healthy adults aged 18 to 60 who are interested in participating in a study involving virtual reality (VR). The goal is to see if new software can help prevent the discomfort some people feel after using VR, known as cybersickness.
What is being tested?
The trial tests Motion Reset software designed to reduce symptoms of cybersickness against a placebo during VR use. Participants will be divided into groups; one with prevention-focused VR experience, another without it, and a control group with no VR.
What are the potential side effects?
Since this study involves healthy volunteers using VR technology, potential side effects may include eye strain, nausea, dizziness or headaches associated with cybersickness. These symptoms are typically mild and resolve after stopping VR use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during vr use
This trial's timeline: 3 weeks for screening, Varies for treatment, and during vr use for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
self-reported cybersickness
Secondary study objectives
discontinuation of VR use

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Intervention: Motion ResetExperimental Treatment1 Intervention
Participate in virtual reality activities
Group II: No interventionActive Control1 Intervention
Group III: Placebo experiencePlacebo Group1 Intervention
Participate in virtual reality activities

Find a Location

Who is running the clinical trial?

National Human Genome Research Institute (NHGRI)Lead Sponsor
264 Previous Clinical Trials
284,149 Total Patients Enrolled
Susan Persky, Ph.D.Principal InvestigatorNational Human Genome Research Institute (NHGRI)
7 Previous Clinical Trials
4,372 Total Patients Enrolled
~100 spots leftby Aug 2025